Two Sigma Advisers’s Jounce Therapeutics, Inc. Common Stock JNCE Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q2 | – | Sell |
-47,800
| Closed | -$88.4K | – | 2770 |
|
|
2023
Q1 | $88.4K | Sell |
47,800
-332,700
| -87% | -$615K | ﹤0.01% | 2399 |
|
|
2022
Q4 | $422K | Buy |
380,500
+96,700
| +34% | +$107K | ﹤0.01% | 1947 |
|
|
2022
Q3 | $664K | Sell |
283,800
-36,700
| -11% | -$85.9K | ﹤0.01% | 1723 |
|
|
2022
Q2 | $971K | Sell |
320,500
-6,000
| -2% | -$18.2K | ﹤0.01% | 1610 |
|
|
2022
Q1 | $2.22M | Sell |
326,500
-199,000
| -38% | -$1.35M | 0.01% | 1194 |
|
|
2021
Q4 | $4.39M | Buy |
525,500
+149,000
| +40% | +$1.24M | 0.01% | 823 |
|
|
2021
Q3 | $2.8M | Buy |
376,500
+158,900
| +73% | +$1.18M | 0.01% | 1070 |
|
|
2021
Q2 | $1.48M | Buy |
217,600
+134,800
| +163% | +$917K | ﹤0.01% | 1447 |
|
|
2021
Q1 | $850K | Buy |
+82,800
| New | +$850K | ﹤0.01% | 1739 |
|
|
2020
Q3 | – | Sell |
-25,300
| Closed | -$175K | – | 2697 |
|
|
2020
Q2 | $175K | Sell |
25,300
-24,100
| -49% | -$167K | ﹤0.01% | 2279 |
|
|
2020
Q1 | $235K | Sell |
49,400
-68,700
| -58% | -$327K | ﹤0.01% | 2113 |
|
|
2019
Q4 | $1.03M | Sell |
118,100
-22,800
| -16% | -$199K | ﹤0.01% | 1564 |
|
|
2019
Q3 | $469K | Sell |
140,900
-11,000
| -7% | -$36.6K | ﹤0.01% | 1737 |
|
|
2019
Q2 | $752K | Sell |
151,900
-41,900
| -22% | -$207K | ﹤0.01% | 1648 |
|
|
2019
Q1 | $1.2M | Sell |
193,800
-73,600
| -28% | -$456K | ﹤0.01% | 1435 |
|
|
2018
Q4 | $901K | Buy |
267,400
+59,700
| +29% | +$201K | ﹤0.01% | 1528 |
|
|
2018
Q3 | $1.35M | Buy |
207,700
+129,200
| +165% | +$840K | ﹤0.01% | 1390 |
|
|
2018
Q2 | $601K | Buy |
+78,500
| New | +$601K | ﹤0.01% | 1845 |
|